LivaNova PLC

LivaNova PLC is a medical technology company that designs, develops, manufactures, and markets medical devices, therapies, and related services. The company operates through two primary segments: Cardiopulmonary and Neuromodulation. Its Cardiopulmonary portfolio includes heart-lung machines, oxygenators, autotransfusion systems, cannulae, and perfusion tubing systems utilized during cardiac surgeries. The Neuromodulation business offers vagus nerve stimulation therapy systems for treating drug-resistant epilepsy and difficult-to-treat depression, along with an implantable neurostimulation system under development for obstructive sleep apnea. LivaNova provides its products to hospitals, medical institutions, and healthcare professionals such as perfusionists, neurologists, and neurosurgeons.

The company distributes its devices in more than 100 countries globally, serving geographic markets in the United States, Europe, and the Rest of the World. A majority of its products are manufactured in facilities located across the United States, Italy, Germany, Australia, and Brazil. Organized under the laws of England and Wales, LivaNova maintains its corporate headquarters in London, England.

Summary of the business section of LivaNova's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, LivaNova had approximately 3,300 employees worldwide, representing more than 80 nationalities and located in 34 countries.”